This is from the SA email: Cellceutix finishes
Post# of 72440
Cellceutix finishes last patient visit in mid-stage Prurisol study in plaque psoriasis; top-line data expected in May
Mar 17 2016, 10:45 ET | About: Cellceutix Corp. (CTIX) | By: Douglas W. House, SA News Editor
Cellceutix (OTCPK:CTIX +1.4%) announces that the last patient visit has been concluded in its Phase 2 clinical trial assessing orally-administered Prurisol (abacavir acetate) for the treatment of mild-to-moderate plaque psoriasis. The unblinding of the study and top-line data are expected in May. The study commenced in August 2015. The product candidate is being developed under the guidance of the FDA's abbreviated 505(b)(2) pathway.
Prurisol is a small molecule that acts through immune modulation and PRINS reduction. PRINS (psoriasis-associated RNA inducted by stress) is a long non-coding RNA overexpressed in psoriatic patients which is believed to contribute to psoriasis via the down regulation of a gene called G1P3, which plays a key role in apoptosis (programmed cell death).
Abacavir acetate is an ester/salt of abacavir sulfate, a nucleoside reverse transcriptase inhibitor branded as Ziagen by ViiV Healthcare for the treatment of HIV-1 infection.